Regarding cancer treatment, preliminary evidence indicates that BRCA1 promoter methylation is associated with sensitivity to a PARP inhibitor in the primary setting in breast cancer [39] while results in metastatic disease are conflicting. This evidence concerns the gene BRCA1 and cancer.